Dechra Pharmaceuticals plc (LON:DPH) has earned an average recommendation of “Buy” from the eight research firms that are presently covering the stock. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is GBX 1,333.86 ($16.66).

A number of research firms have commented on DPH. Stifel Nicolaus reissued a “hold” rating and issued a GBX 1,250 ($15.62) target price on shares of Dechra Pharmaceuticals plc in a report on Friday, October 21st. N+1 Singer lifted their target price on Dechra Pharmaceuticals plc from GBX 1,350 ($16.87) to GBX 1,412 ($17.64) and gave the stock a “buy” rating in a report on Friday, October 21st. Jefferies Group lifted their target price on Dechra Pharmaceuticals plc from GBX 1,229 ($15.35) to GBX 1,295 ($16.18) and gave the stock a ” hold” rating in a report on Wednesday, September 7th. Investec lifted their target price on Dechra Pharmaceuticals plc from GBX 1,300 ($16.24) to GBX 1,400 ($17.49) and gave the stock a “buy” rating in a report on Monday, September 5th. Finally, Numis Securities Ltd restated an “add” rating and issued a GBX 1,520 ($18.99) price target on shares of Dechra Pharmaceuticals plc in a research note on Thursday, October 27th.

Shares of Dechra Pharmaceuticals plc (LON:DPH) opened at 1293.00 on Friday. Dechra Pharmaceuticals plc has a 1-year low of GBX 811.00 and a 1-year high of GBX 1,462.00. The company’s market capitalization is GBX 1.20 billion. The company’s 50 day moving average price is GBX 1,343.27 and its 200-day moving average price is GBX 1,261.65.

The business also recently announced a dividend, which was paid on Friday, November 18th. Investors of record on Thursday, October 27th were given a dividend of GBX 12.91 ($0.16) per share. The ex-dividend date was Thursday, October 27th. This is an increase from Dechra Pharmaceuticals plc’s previous dividend of $5.55. This represents a yield of 0.92%.

WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of international copyright and trademark laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/23/dechra-pharmaceuticals-plc-dph-receives-consensus-recommendation-of-buy-from-brokerages-2.html.

About Dechra Pharmaceuticals plc

Dechra Pharmaceuticals PLC is a veterinary pharmaceuticals company. The Company is engaged in the development, manufacture and marketing of products for veterinarians across the world. The Company’s segments include European Pharmaceuticals, consists of Dechra Veterinary Products EU and Dechra Pharmaceuticals Manufacturing; North American (NA) Pharmaceuticals, consists of Dechra Veterinary Products US and Dechra Veterinary Products Canada, and Pharmaceuticals Research and Development.

Receive News & Stock Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related stocks with our FREE daily email newsletter.